Ukukhetha okuthandwayo kokuphathwa kwesicanucanu nokuhlanza okubangelwa yi-chemotherapy (CINV). Isicanucanu nokuhlanza okubangelwa yi-chemotherapy (CINV) kungenye yezindlela ezimbi ezesatshwa kakhulu phakathi kweziguli ezithola ukwelashwa komdlavuza, okuthinta kakhulu ukuhambisana nokwelashwa kanye nekhwalithi yokuphila. Njengesizukulwane esisha sama-NK1 receptor antagonists, i-Fosaprepitant Dimeglumine, enezakhiwo zayo zemithi zokukhetha okuphezulu kanye nokuhambisana okuphezulu, ingavimba kakhulu indlela yokubonisa ukuhlanza eqondiswa yi-substance P.
Imininingwane yezokwelapha iqinisekisa ukuthi lo mkhiqizo ubonisa imiphumela emihle kakhulu yokulawula isicanucanu esibukhali nesiphuzile kanye nokuhlanza okubangelwa yi-highly emetogenic chemotherapy (HEC) kanye ne-moderate emetogenic chemotherapy (MEC). Ukunikezwa komthamo owodwa kungafeza i-antiemesis esebenza isikhathi eside ngokubekezelela okuhle. Uma kuhlanganiswa nama-5-HT3 receptor antagonists kanye ne-dexamethasone, kwakha uhlelo lokuvikela lwe-CINV oluphelele nolusebenza ngokugcwele.
Kusukela ekusetshenzisweni kalula kuya ekuqineni kokusebenza kahle, i-Fosaprepitant Dimeglumine inikeza ukukhetha okungcono komkhuba wezokwelapha, isiza iziguli ukuthi zidlule umjikelezo we-chemotherapy kahle futhi zenze ukwelashwa komdlavuza kube nobubele kakhulu.
Isikhathi sokuthunyelwe: Disemba-09-2025
